1800 202 8726
Biopsy myths

Does Biopsy Spread Cancer? — What the Evidence Actually Says

The fear that a biopsy needle will carry cancer cells into healthy tissue causes some people to refuse the only test that can confirm a diagnosis. The evidence on how often this actually happens — and what it means when it does — is worth understanding before that decision is made.

Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed September 2026

  • It is documented but extremely rare — Needle track seeding is a recognised phenomenon, but the rate across most cancer types is vanishingly low.
  • It almost never changes the outcome — In the rare cases it occurs, the displaced cells are usually treated effectively and do not alter the overall prognosis.
  • Refusing a biopsy has a real cost — Without a biopsy, there is no confirmed diagnosis, and without a diagnosis, treatment cannot begin.
  • Modern techniques reduce the risk further — Coaxial needles and image guidance have lowered even the already-rare event.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Needle track seeding — where a biopsy needle carries cells along its path — is documented but extremely rare. ASCO and ESMO consistently describe it as uncommon across most cancer types. In almost all reported cases, the seeded cells are treatable and do not change the overall outcome. The risk of no diagnosis far outweighs the risk of seeding.

Does a biopsy needle spread cancer cells?

A biopsy spreads cancer through the body.

Needle track seeding is a localised event, not a systemic one. The rare cases documented in research involve cells displaced along a short needle path — not cancer seeded throughout the body. Spread through the bloodstream or lymphatic system is a property of the cancer's own biology, not of the biopsy procedure.

Doctors hide the seeding risk because the rates are high.

The rates are low, which is exactly why seeding is not routinely foregrounded in consent conversations for most biopsy types. It is not concealed — it is documented in published ASCO and ESMO guidance. For some cancer types, particularly hepatocellular carcinoma, the risk is discussed directly because it is more clinically relevant there.

If seeding happens, it is as serious as a new cancer.

Seeded cells along a needle track are not a new primary cancer. They are a small cluster from a tumour that already exists and is already being treated. In reported cases, the track is often covered by radiation or removed surgically. ESMO guidance notes that seeding rarely alters the overall treatment plan.

Avoiding a biopsy keeps you safer.

Without a biopsy, your cancer type, grade and molecular profile cannot be confirmed. Treatment cannot be tailored. In a proportion of patients, tumours that appear similar on imaging have completely different biology and require different treatments. The consequence of no diagnosis is not theoretical — it is the absence of any treatment.

What does 'needle track seeding' mean?

Needle track seeding (also: tract seeding)
The displacement of cancer cells along the path a biopsy needle travels through tissue. A documented phenomenon in the medical literature, reported at very low rates for most cancer types. Also called needle tract implantation.
Core needle biopsy
A biopsy that removes a small cylinder of tissue using a hollow needle. It gives more material for analysis than a fine needle technique and is the standard approach for many solid tumours. Most seeding research focuses on this type.
Fine needle aspiration (FNA)
A biopsy using a thinner needle to draw out cells rather than a tissue core. Generally associated with even lower seeding rates than core needle techniques in the published literature.
Coaxial technique
A biopsy method where a guide sleeve is placed first and the biopsy needle passes through it repeatedly. This reduces needle passes through outer tissue and is associated with lower seeding risk in published comparisons.
Clinically significant seeding
Seeding that actually changes a patient's outcome — requiring additional treatment or affecting prognosis. This is rarer than seeding itself, because a proportion of displaced cells do not establish or grow.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What should you ask before your biopsy?

  • Ask which biopsy technique is planned — core needle, FNA, or coaxial — and why it was chosen for your cancer type.
  • Ask whether image guidance such as ultrasound or CT will be used, which reduces the number of needle passes needed.
  • Tell your team you have read about seeding risk. They can give you the rate specific to your cancer type rather than a general answer.
  • Ask what information the biopsy will give that imaging alone cannot, so you understand what is at stake without it.
  • Ask whether the biopsy site will be included in your planned radiation field — this is already standard practice in many protocols.

Did you know?

Most of the widely cited seeding data comes from a small number of specific cancer types — particularly hepatocellular carcinoma — and does not represent the rate for biopsies performed across all cancer types worldwide.

For the majority of solid tumours, ASCO and ESMO guidance describes seeding as rare enough that it does not affect the recommendation to biopsy.

Source: ASCO and ESMO clinical practice guidelines on tissue sampling and biopsy safety

Explore 71 more Understanding Your Biopsy and Whether You Need One topics

HUB — Does a Biopsy Spread Cancer? Myths and Evidence

HUB — What Is a Biopsy? Everything You Need to Know

All Understanding Your Biopsy and Whether You Need One →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Has needle track seeding ever actually caused harm?

Yes, it has been documented in the medical literature, most often in hepatocellular carcinoma and a small number of other cancer types. What the literature also shows is that when it occurs, the seeded cells are usually detected and treated — with radiation to the track, surgical removal, or both. ESMO guidance acknowledges the phenomenon while maintaining that biopsy remains the standard approach, because the risk of proceeding without a tissue diagnosis is greater than the risk of seeding.

Is liver cancer biopsy more risky for seeding than other biopsies?

Hepatocellular carcinoma is the cancer type most associated with seeding in the published literature. For this reason, some liver cancer protocols now use imaging criteria to confirm diagnosis without biopsy when those criteria are met. This is not because biopsy is unsafe, but because a validated alternative pathway exists for that specific cancer. For most other cancers, there is no imaging substitute for tissue diagnosis, and the seeding rate does not change the recommendation to biopsy.

Does the biopsy needle carry cancer cells into my bloodstream?

The concern that biopsy causes systemic spread — cancer entering the blood and reaching other organs — is not supported by the evidence. Needle track seeding is a localised event involving cells displaced along the short path the needle travels. If biopsy were sending cancer cells into the bloodstream in meaningful numbers, you would expect to see higher rates of distant recurrence after biopsy. Studies examining this have not found that pattern. Distant spread is a property of the tumour's own biology.

What happens if seeding does occur?

The most common approach is to include the biopsy site within the radiation field when radiation is part of your treatment plan — this is already standard in many protocols. If the seeded site is accessible, surgical removal is another option. Because seeded cells come from a tumour your team is already treating, their management is usually incorporated into your overall treatment rather than handled as a separate problem. In a proportion of cases, seeded cells do not establish or grow at all.

Should I refuse a biopsy because of seeding risk?

That is a decision only you can make, and your oncologist will respect it. What is worth knowing first is what you lose without a biopsy: your cancer type cannot be confirmed, molecular testing cannot be done, and treatment cannot be tailored to your tumour. In a proportion of patients, what imaging suggests and what the biopsy reveals do not match. The question to weigh is not whether seeding can happen, but whether its rare and usually manageable occurrence outweighs the certainty of having no diagnosis at all.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation